Data from Hamilton Health Sciences Broaden Understanding of Carcinomas (Efficacy and Safety of Lenvatinib in Combination With Other Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma).

MLA

“Data from Hamilton Health Sciences Broaden Understanding of Carcinomas (Efficacy and Safety of Lenvatinib in Combination With Other Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma).” Clinical Oncology Week, Nov. 2024, p. 289. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=180749085&authtype=sso&custid=ns315887.

APA

Data from Hamilton Health Sciences Broaden Understanding of Carcinomas (Efficacy and Safety of Lenvatinib in Combination With Other Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma). (2024). Clinical Oncology Week, 289.

Chicago

“Data from Hamilton Health Sciences Broaden Understanding of Carcinomas (Efficacy and Safety of Lenvatinib in Combination With Other Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma).” 2024. Clinical Oncology Week, November, 289. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=180749085&authtype=sso&custid=ns315887.